A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Amgen
- 07 Aug 2017 Planned End Date changed from 16 Sep 2020 to 5 Oct 2019.
- 07 Aug 2017 Planned primary completion date changed from 23 Jan 2019 to 16 Jan 2019.
- 20 Jun 2017 Planned number of patients changed from 50 to 38.